Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1958 1
1971 2
1973 1
1985 1
1986 1
1990 1
1992 1
1993 2
1994 3
1995 3
1996 3
1997 1
1998 1
1999 2
2000 2
2001 5
2002 1
2003 3
2004 4
2005 8
2006 5
2007 10
2008 9
2009 4
2010 20
2011 26
2012 13
2013 19
2014 16
2015 26
2016 16
2017 19
2018 18
2019 20
2020 23
2021 35
2022 29
2023 29
2024 46
2025 39

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

412 results

Results by year

Filters applied: . Clear all
Page 1
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Marso SP, et al. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. N Engl J Med. 2016. PMID: 27633186 Free article. Clinical Trial.
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP; ARANOTE Study Investigators. Saad F, et al. J Clin Oncol. 2024 Dec 20;42(36):4271-4281. doi: 10.1200/JCO-24-01798. Epub 2024 Sep 16. J Clin Oncol. 2024. PMID: 39279580 Free PMC article. Clinical Trial.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Smith MR, et al. N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17. N Engl J Med. 2022. PMID: 35179323 Free PMC article. Clinical Trial.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. Among authors: luz m. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. Shore ND, et al. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469183 Clinical Trial.
Subcutaneous versus intravenous nivolumab for renal cell carcinoma.
Albiges L, Bourlon MT, Chacón M, Cutuli HJ, Chuken YAL, Żurawski B, Mota JM, Magri I, Burotto M, Luz M, de Menezes J, Ruiz EPY, Fu S, Richardet M, Valderrama BP, Maruzzo M, Bracarda S, Breckenridge M, Vezina HE, Rathod D, Yu Z, Zhao Y, Dixon M, Perumal D, George S. Albiges L, et al. Among authors: luz m. Ann Oncol. 2025 Jan;36(1):99-107. doi: 10.1016/j.annonc.2024.09.002. Epub 2024 Sep 15. Ann Oncol. 2025. PMID: 39288844 Free article. Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. Among authors: luz m. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Free article. Clinical Trial.
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
Catto JWF, Tran B, Rouprêt M, Gschwend JE, Loriot Y, Nishiyama H, Redorta JP, Daneshmand S, Hussain SA, Cutuli HJ, Procopio G, Guadalupi V, Vasdev N, Naini V, Crow L, Triantos S, Baig M, Steinberg G; THOR-2 Cohort 1 Investigators. Catto JWF, et al. Ann Oncol. 2024 Jan;35(1):98-106. doi: 10.1016/j.annonc.2023.09.3116. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871701 Free article. Clinical Trial.
412 results